Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Drug therapy in patients with chronic low back pain is a major challenge for physicians. One
of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient.
Usually one of the classes of pain medication is given to patients with a similar clinical
picture, although different pain mechanisms may be responsible for this clinical picture.
Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason
why an unique drug produces different responses (from a lacking analgesic effect up to
excessive effect or side-effects.
Quantitative sensory testing is a method that documents alterations in the pain perception
system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for
anticipation of drug efficacy.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Collaborators:
Aalborg University University of Bern University of Zurich